title: Allergic reactions to oxaliplatin in a single institute in Japan.
abstract: Allergic reactions to oxaliplatin can be severe and are an important cause of discontinuation of treatment. A retrospective review was performed for 105 patients who received FOLFOX regimens between May 2005 and June 2007. Twenty-five cases (23.8%) of allergic reactions were identified, including 9 late onset reactions (8.6%) and 16 immediate reactions (15.2%). Severe allergy (Grades 3 and 4) occurred in seven patients (6.7%). Re-introduction of FOLFOX was attempted for seven immediate onset patients with a severity grade of 1 or 2, and three of these patients (42.9%) showed relapse of allergy. In approximately 10% of the patients, FOLFOX had to be discontinued due to allergy before the disease became refractory to the regimen. Our experience indicates that allergy to oxaliplatin may be a significant concern and that methods are required for suppression of this allergy.
authors: Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. yasu0514@med.yokohama-cu.ac.jp.
authors: Yasushi
authors: Y
authors: Ichikawa
authors: Ayumu
authors: A
authors: Goto
authors: Satoru
authors: S
authors: Hirokawa
authors: Miyuki
authors: M
authors: Kijima
authors: Takashi
authors: T
authors: Ishikawa
authors: Takashi
authors: T
authors: Chishima
authors: Hirokazu
authors: H
authors: Suwa
authors: Harumi
authors: H
authors: Yamamoto
authors: Shigeru
authors: S
authors: Yamagishi
authors: Shunichi
authors: S
authors: Osada
authors: Mitsuyoshi
authors: M
authors: Ota
authors: Shoichi
authors: S
authors: Fujii
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D007564:Japan; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil